About iXpressGenes
iXpressGenes is a company based in Huntsville (United States) founded in 2006. iXpressGenes has raised $2.37 million across 6 funding rounds from investors including HHS. iXpressGenes offers products and services including TAI Screening. iXpressGenes operates in a competitive market with competitors including Stoke Therapeutics, CureVac, Vico, ReNAgade and EnPlusOne Bio, among others.
- Headquarter Huntsville, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$2.37 M (USD)
in 6 rounds
-
Latest Funding Round
$1.11 M (USD), Grant
Aug 15, 2015
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of iXpressGenes
iXpressGenes offers a comprehensive portfolio of products and services, including TAI Screening.
Blood test to detect biomarkers for trauma-related diseases early
People of iXpressGenes
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of iXpressGenes
iXpressGenes has successfully raised a total of $2.37M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $1.11 million completed in August 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in iXpressGenes
iXpressGenes has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for iXpressGenes
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by iXpressGenes
Investment portfolio details for iXpressGenes
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - iXpressGenes
Detailed financials for iXpressGenes
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ixpressgenes Comparisons
Peer comparison for iXpressGenes
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of iXpressGenes
iXpressGenes operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Stoke Therapeutics, CureVac, Vico, ReNAgade and EnPlusOne Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of antisense oligonucleotide drugs for treating inherited diseases by targeting RNA splicing
|
|
| Locked | Locked | Locked |
mRNA-based therapeutics against cancer and infectious diseases are developed.
|
|
| Locked | Locked | Locked |
RNA modulating therapies for genetic neurological diseases are developed.
|
|
| Locked | Locked | Locked |
RNA-based medicines are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Developer of RNA synthesis platform for gene therapeutics
|
|
| Locked | Locked | Locked |
Small activating RNA therapeutics are developed to restore gene function.
|
Detailed competitors of iXpressGenes
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ixpressgenes
Complete news archive for iXpressGenes
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about iXpressGenes
iXpressGenes was founded in 2006 and raised its 1st funding round 2 years after it was founded.
iXpressGenes is headquartered in Huntsville, United States. It is registered at Huntsville, Alabama, United States.
iXpressGenes is a funded company, having raised a total of $2.37M across 6 funding rounds to date.
iXpressGenes was founded in 2006 and is based in Huntsville, United States. Operations focus on synthetic biology and protein engineering, with services centered on extremozymes from hyperthermophilic genomes sourced from Atlantic Ridge deep sea vents. Expertise includes microgravity experiments conducted on the International Space Station and optimized trace fluorescent labeling for protein crystallization. Instrumentation supports high-throughput biology research.
iXpressGenes's top competitors include MiNA Therapeutics, Vico and Stoke Therapeutics.
iXpressGenes offers TAI Screening.
iXpressGenes has 1 investor. Key investors include HHS.